Carotid Artery OcclusionNCT07396025
Effectiveness of Surgical and Diagnostic Methods in Cerebral Vascular Occlusive Disease
A study testing Revascularization/Conservative management in people with Carotid Artery Occlusion, run by National Centre for Neurosurgery, Republic of Kazakhstan at 1 site in Kazakhstan.
Trial summary
This study attempts to improve surgical treatment outcomes among people with chronic carotid artery occlusive disease by conducting a comprehensive review of neuroradiological, clinical, and cognitive data. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Carotid Artery Occlusion
- What is being tested?
- Revascularization/Conservative management
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteKazakhstan
- Study dates
- 9 Jul 2025to 31 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with ICA occlusion confirmed by CTA, MRA, and cerebral DSA.
- MRI ASL-confirmed hypoperfusion in the territory of the occluded ICA (decrease of ≥30% compared with the contralateral side)
- Language comprehension is preserved, with mild or no motor aphasia and no significant cognitive impairment.
- Patients aged from 18 to 80 years.
- Modified Rankin Scale (mRS) score 0-2.
- Informed consent is available from the patient or legal guardian.
- Accessible and reliable patients for follow-up
Who cannot join
- Patients with large territorial infarction or marked cerebral atrophy on MRI.
- No evidence of regional hypoperfusion on ASL MRI relative to the contralateral hemisphere.
- Patients with a non-functioning STA-MCA bypass
- Patients aged under 18
- Patients with severe somatic conditions or mRS score > 3
- Patients with bilateral ICA occlusion, neurovascular disease (cerebral aneurysm or arteriovenous malformation)
Show all 13Show fewer
- Patients with Contraindications to MRI, CTA, or DSA
- Cardiac conditions associated with a high risk of cerebral embolism, including prosthetic heart valves, infective endocarditis, intracardiac thrombus, sick sinus syndrome, cardiac myxoma, or cardiomyopathy with left ventricular ejection fraction <25% (atrial fibrillation, patent foramen ovale, and atrial septal aneurysm are not exclusion criteria).
- Severe systemic comorbidities, life expectancy <2 years, or a modified Rankin Scale (mRS) score >3.
- Pregnancy.
- Contraindications to MRI, CTA, DSA, iodinated contrast agents, or antiplatelet therapy required in the perioperative period.
- Participation in another interventional or experimental trial within the previous 12 months, including studies involving ionizing radiation
- -
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Evaluation of the Effectiveness of Surgical and Diagnostic Techniques in Patients With Steno-occlusive Diseases of the Cerebral Vessels
This study attempts to improve surgical treatment outcomes among people with chronic carotid artery occlusive disease by conducting a comprehensive review of neuroradiological, clinical, and cognitive data. The evaluation involves an extensive angiographic analysis, including pre- and postoperative measurements of superficial temporal artery branch diameters, assessment of the Circle of Willis and collateral pathways, alongside cerebral perfusion metrics, cognitive status, and clinical outcomes. Major focus is directed towards evaluating the degree of intracranial revascularization following to extracranial-intracranial bypass by postoperative angiographic evaluations. This integrative strategy aims to refine surgical reasons, better predictions of functional and cognitive outcomes, minimize postoperative risks, and eventually improve the overall efficacy of treatment in this patient population.
Read the detailed description
Patient selection. Patients with asymptomatic or symptomatic ICA occlusion undergoing STA-MCA bypass at the neurosurgical center will be prospectively enrolled between August 2025 and December 2027. Prior to registration, all participants will provide written informed permission in compliance of the Declaration of Helsinki's ethical guidelines.
Preoperative evaluation will include computed tomography angiography (CTA), magnetic resonance imaging (MRI), digital subtraction angiography (DSA), and comprehensive neurological and neuropsychological assessments. Magnetic Resonance Imaging also will be employed to exclude patients with extensive territorial infarctions. Only patients with radiologically confirmed ICA occlusion and arterial spin labeling (ASL) MRI-documented cerebral hypoperfusion in the affected vascular territory who undergo STA-MCA bypass will be included.
The study cohort will be recruited at the National Center for Neurosurgery in Astana through a multidisciplinary collaboration involving neurosurgeons, radiologists, neurologists, and neuropsychologists. All data will be collected using standardized case report forms and subsequently entered into a unified, secure database. Patient confidentiality will be ensured through strict coding and anonymization of personal identifiers and medical record identification numbers (MRINs).
Study variables. Data collection will include the following variables:
Demographic characteristics: Age, gender, birthplace, nationality, employment status, profession, and education level. Medical history: Past medical and surgical history, onset of TIA or stroke, vascular risk factors (hypertension, diabetes mellitus, dyslipidemia, atrial fibrillation), comorbidities (including genetic disorders), previous surgeries, ongoing follow-up care, current medications, and BMI. Clinical, neurological, and cognitive status: Baseline neurological examination findings, Modified Rankin Scale (mRS) and National Institutes of Health Stroke Scale (NIHSS) scores, history of seizures, quality-of-life measures, cognitive reserve indicators (educational attainment and occupational complexity), and engagement in cognitively stimulating activities will be assessed. Lifestyle factors: Smoking status, dietary habits, physical activity, alcohol consumption, sleep quality, vacation frequency, tobacco use, and other lifestyle factors. Radiological and hemodynamic parameters: Location and length of the internal carotid artery occlusion; collateral circulation patterns; Circle of Willis configuration; ASL perfusion metrics; cerebral blood flow (CBF) asymmetry indices; infarct burden; white matter hyperintensities; and postoperative bypass patency and the diameter of STA pre and postoperatively.
Study procedures. To evaluate the ICA occlusion, a three-level assessment will be conducted using instrumental methods. This comprehensive approach includes CTA of the head and neck vessels, specialized MRI ASL and Time-of-flight (TOF) sequences, and a confirmatory assessment of occlusion during DSA. All imaging studies will be performed and interpreted by experienced neuroradiologists and neurosurgeons, with findings reviewed collaboratively.
All patients will undergo CTA of the head and neck vessels with a slice thickness of 0.5-0.625 mm to confirm internal carotid artery occlusion and to measure the diameter of the donor STA branch at 2 mm distal to its bifurcation.
To evaluate cerebral blood flow (CBF) and determine the extent of cerebrovascular insufficiency, MRI perfusion studies will be conducted before surgery on 1,5 or 3 Tesla MRI. The main perfusion method will be ASL, which will provide quantitative CBF values, assess the degree of perfusion deficit, and reveal signs of compensatory collateral circulation based on the presence of arterial transit artifacts (ATA). Selective cerebral angiography will be performed using a biplane digital subtraction angiography system (Artis Zee, Siemens) with a 6F guiding catheter at a frame rate of 7.5 frames per second. The angiographic assessment will evaluate the presence of communicating arteries, the completeness of the Circle of Willis, and the extent of collateral circulation. Hemodynamic compensation will be quantified by analyzing filling times and phase delays across the arterial, parenchymal, and venous phases, expressed in frames. Image analysis will be conducted using Siemens Artis Q angiography software to ensure accurate and reproducible measurements.
Neurological status assessment. The degree of neurological deficit before and after surgery will be evaluated by neurologist using the Baseline neurological examination findings, Modified Rankin Scale (mRS) and National Institutes of Health Stroke Scale (NIHSS) scores). The consequences of prior stroke will also be assessed with the modified Rankin Scale (mRS)15 and the Functional Activities Questionnaire (FAQ)16. Preoperatively and six months after surgery, all patients will be evaluated under a unified diagnostic protocol, with results collected and recorded separately before entering them into a general database with strict personal data encoding.
Cognitive function assessment. Changes in cognitive function before and after surgery and six months postoperatively will be assessed using the neuropsychological tests, measuring both verbal and non-verbal IQ. A standardized battery of neuropsychological tests will be administered by a psychologist to evaluate global cognition, memory, visuospatial skills, and executive function. The Montreal Cognitive Assessment (MoCA) will be used as a screening tool for global cognitive function, assessing domains including attention, executive functions, memory, language, visuospatial skills, abstraction, and orientation17. The Rey Auditory Verbal Learning Test (RAVLT) will be employed to evaluate verbal learning and memory performance, including immediate recall, delayed recall, and recognition memory18. Nonverbal test of Kohs Block Design will be used to assess visuospatial reasoning, problem-solving, and perceptual-motor coordination by requiring participants to reproduce geometric patterns with colored blocks19. The Stroop Test will be applied to measure selective attention, processing speed, and cognitive flexibility by evaluating the ability to inhibit cognitive interference20.
Treatment. All eligible patients with ICA occlusion will undergo standard STA-MCA bypass surgery performed by experienced neurosurgeons. The procedure will be carried out using a standardized microsurgical end-to-side anastomosis technique, which is well established and routinely performed by the participating surgeons21. Intraoperative selection of the donor STA branch and recipient MCA segment will be based on vessel diameter, flow characteristics, and surgical accessibility. Intraoperative bypass patency will be assessed using the "faucet" technique21 in combination with microscopic indocyanine green (ICG) angiography to ensure adequate flow through the anastomosis.
Intraoperative perfusion and blood flow direction assessment Intraoperative perfusion and blood flow direction will be assessed using indocyanine green fluorescent angiography with the Karl Zeiss Pentera 8000 microscope equipped with FLOW 800 technology, which allows real-time visualization of cerebral vessels. All data will be processed and analyzed to create a color map depicting hemodynamic and perfusion delays. This enables comparison of perfusion parameters in the anastomosis region before and after bypass surgery, as well as assessment of blood flow direction and hyperperfusion zones in the brain. The assessment will be performed by neurosurgeons.
Postoperative study procedures.Within 1-3 days after surgery, CTA of the head and neck will be performed to confirm bypass patency, measure the caliber of the donor STA branch, and visualize its course. At 3-5 days postoperatively, ASL-based MR perfusion imaging will be conducted to evaluate cerebral perfusion changes compared with preoperative studies. 3D segmentation and quantitative perfusion mapping will be applied to provide objective assessment of regional perfusion improvements following surgery. Prior to hospital discharge, all patients will undergo a repeat evaluation of neurological status and cognitive function using the same standardized tests as preoperatively.
Follow-up assessment. At six months after surgery, all patients will undergo follow-up assessment including CTA of the head and neck to evaluate bypass patency and measure the caliber of the donor STA branch, MR perfusion imaging with 3D segmentation to assess cerebral perfusion changes, and repeat neurological and neuropsychological evaluations using the same tests administered preoperatively and at discharge (NIHSS, mRS, MoCA, RAVLT, Kohs Block Design, and Stroop tests).
Endpoint evaluation
Primary endpoints (early postoperative assessment):
- Bypass patency assessed by CTA within 1-3 days postoperatively.
- Cerebral perfusion improvement evaluated by ASL MR perfusion imaging 3-5 days postoperatively, including 3D segmentation and quantitative perfusion mapping, as well as assessment for the presence of cerebral hyperperfusion syndrome.
- Surgical safety outcomes, including perioperative stroke, transient ischemic attack (TIA), or other procedure-related complications.
Secondary endpoints (six-month follow-up):
- Clinical outcomes: Occurrence of any stroke events or death.
- Imaging outcomes: CTA of the head and neck to assess long-term bypass patency and measure the caliber of the donor STA branch and MR perfusion imaging wit to evaluate sustained cerebral perfusion changes.
- Functional and cognitive function improvements: Neurological and neuropsychological assessments using the same standardized tests as preoperatively and at discharge.
- MRI perfusions pre and postoperatively after 6 months will be compared in 3 D program models and correlated with neurological and cognitive changes, and additional correlations with donor branch of STA Data processing. All collected data will be meticulously entered into a database, where revascularization progress, the development of collateral circulation, and perfusion changes correlated with neurological and cognitive shifts will be evaluated. All data will undergo statistical processing and analysis to identify patterns and correlations, as well as survival analysis to assess collateral development and psychoneurological dynamics. All participants are expected to complete study visits over the planned 6-months follow-up period.
- Conditions
- Carotid Artery Occlusion
- Being tested
- Revascularization/Conservative management
- Keywords
- stroke, carotid artery occlusion, cerebral bypass, STA-MCA bypass, atherosclerosis, CT and MRI perfusion, cerebral angiography, stroke, carotid artery occlusion, cerebral bypass, STA-MCA bypass, atherosclerosis, CT and MRI perfusion, cerebral angiograph
- Medical subject headings
- Stroke, Atherosclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Revascularization/Conservative managementProcedure or surgery
This study attempts to improve surgical treatment outcomes among people with chronic carotid artery occlusive disease by conducting a comprehensive review of neuroradiological, clinical, and cognitive data. The evaluation involves an extensive angiographic analysis, including pre- and postoperative measurements of superficial temporal artery branch diameters, assessment of the Circle of Willis and collateral pathways, alongside cerebral perfusion metrics, cognitive status, and clinical outcomes. Major focus is directed towards evaluating the degree of intracranial revascularization following to extracranial-intracranial bypass by postoperative angiographic evaluations.
| Study group | Role | What they receive |
|---|---|---|
| patients with chronic occlusive internal carotid artery cerebrovascular disease | Other | Not described Receives: Procedure: Revascularization/Conservative management |
What is being measured
The primary outcome is the main question the study is designed to answer.
STA-MCA bypass patency
Patency of the extracranial-intracranial bypass will be assessed using CTA of the head and neck and classified as patent or occluded.
Measured: From enrollment to the further follow-up of 6, 12, and 24 months.
Donor superficial temporal artery caliber
Diameter of the donor superficial temporal artery branch at the anastomosis site measured using CTA imaging.
Measured: 6, 12, and 24 months after surgery
Cerebral perfusion changes
Quantitative cerebral perfusion parameters assessed using MR perfusion imaging with 3D segmentation and compared with preoperative baseline values.
Measured: 6, 12, and 24 months after surgery
Secondary outcomes (1)
Global cognitive function
Cognitive performance assessed using the Montreal Cognitive Assessment (MoCA).
Measured: Preoperatively; at discharge; 6, 12, and 24 months after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Feb 2026
- Study start9 Jul 2025
- Primary completionDec 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Carotid Artery OcclusionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National Centre for Neurosurgery, Republic of Kazakhstan
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07396025
- Sponsor's protocol ID
- 26100905
- Other IDs
- AP26100905
- Status last verified
- Feb 2026
- First submitted
- 28 Jan 2026
- Last updated
- 9 Feb 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Nurimanov C, Menlibayeva K, Mammadinova I, Turzhanova A, Aidarov S, Batyrkhanov D, Kabykenova A, Makhambetov Y, Kaliyev A. Hemodynamic, neurological, and cognitive outcomes after surgical revascularisation in occlusive cerebrovascular disease: Study protocol for single-arm interventional cohort study. PLoS One. 2026 Aug 7;21(8):e0354103. doi: 10.1371/journal.pone.0354103. eCollection 2026.
PubMed 42566397
Study at a glance
From the registry record, last updated by the sponsor on 9 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Effectiveness of Surgical and Diagnostic Techniques in Patients With Steno-occlusive Diseases of the Cerebral Vessels
- ClinicalTrials.gov ID
- NCT07396025
- Acronym / sponsor ID
- 26100905
- Conditions
- Carotid Artery Occlusion
- Keywords
- stroke, carotid artery occlusion, cerebral bypass, STA-MCA bypass, atherosclerosis, CT and MRI perfusion, cerebral angiography, stroke, carotid artery occlusion, cerebral bypass, STA-MCA bypass, atherosclerosis, CT and MRI perfusion, cerebral angiograph
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- National Centre for Neurosurgery, Republic of KazakhstanUniversity, hospital or other
- Study start
- 9 Jul 2025 (actual)
- Primary completion
- Dec 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 9 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study attempts to improve surgical treatment outcomes among people with chronic carotid artery occlusive disease by conducting a comprehensive review of neuroradiological, clinical, and cognitive data. The evaluation involves an extensive angiographic analysis, including pre- and postoperative measurements of superficial temporal artery branch diameters, assessment of the Circle of Willis and collateral pathways, alongside cerebral perfusion metrics, cognitive status, and clinical outcomes. Major focus is directed towards evaluating the degree of intracranial revascularization following to extracranial-intracranial bypass by postoperative angiographic evaluations. This integrative strategy aims to refine surgical reasons, better predictions of functional and cognitive outcomes, minimize postoperative risks, and eventually improve the overall efficacy of treatment in this patient population.
Detailed description
Patient selection. Patients with asymptomatic or symptomatic ICA occlusion undergoing STA-MCA bypass at the neurosurgical center will be prospectively enrolled between August 2025 and December 2027. Prior to registration, all participants will provide written informed permission in compliance of the Declaration of Helsinki's ethical guidelines.
Preoperative evaluation will include computed tomography angiography (CTA), magnetic resonance imaging (MRI), digital subtraction angiography (DSA), and comprehensive neurological and neuropsychological assessments. Magnetic Resonance Imaging also will be employed to exclude patients with extensive territorial infarctions. Only patients with radiologically confirmed ICA occlusion and arterial spin labeling (ASL) MRI-documented cerebral hypoperfusion in the affected vascular territory who undergo STA-MCA bypass will be included.
The study cohort will be recruited at the National Center for Neurosurgery in Astana through a multidisciplinary collaboration involving neurosurgeons, radiologists, neurologists, and neuropsychologists. All data will be collected using standardized case report forms and subsequently entered into a unified, secure database. Patient confidentiality will be ensured through strict coding and anonymization of personal identifiers and medical record identification numbers (MRINs).
Study variables. Data collection will include the following variables:
Demographic characteristics: Age, gender, birthplace, nationality, employment status, profession, and education level. Medical history: Past medical and surgical history, onset of TIA or stroke, vascular risk factors (hypertension, diabetes mellitus, dyslipidemia, atrial fibrillation), comorbidities (including genetic disorders), previous surgeries, ongoing follow-up care, current medications, and BMI. Clinical, neurological, and cognitive status: Baseline neurological examination findings, Modified Rankin Scale (mRS) and National Institutes of Health Stroke Scale (NIHSS) scores, history of seizures, quality-of-life measures, cognitive reserve indicators (educational attainment and occupational complexity), and engagement in cognitively stimulating activities will be assessed. Lifestyle factors: Smoking status, dietary habits, physical activity, alcohol consumption, sleep quality, vacation frequency, tobacco use, and other lifestyle factors. Radiological and hemodynamic parameters: Location and length of the internal carotid artery occlusion; collateral circulation patterns; Circle of Willis configuration; ASL perfusion metrics; cerebral blood flow (CBF) asymmetry indices; infarct burden; white matter hyperintensities; and postoperative bypass patency and the diameter of STA pre and postoperatively.
Study procedures. To evaluate the ICA occlusion, a three-level assessment will be conducted using instrumental methods. This comprehensive approach includes CTA of the head and neck vessels, specialized MRI ASL and Time-of-flight (TOF) sequences, and a confirmatory assessment of occlusion during DSA. All imaging studies will be performed and interpreted by experienced neuroradiologists and neurosurgeons, with findings reviewed collaboratively.
All patients will undergo CTA of the head and neck vessels with a slice thickness of 0.5-0.625 mm to confirm internal carotid artery occlusion and to measure the diameter of the donor STA branch at 2 mm distal to its bifurcation.
To evaluate cerebral blood flow (CBF) and determine the extent of cerebrovascular insufficiency, MRI perfusion studies will be conducted before surgery on 1,5 or 3 Tesla MRI. The main perfusion method will be ASL, which will provide quantitative CBF values, assess the degree of perfusion deficit, and reveal signs of compensatory collateral circulation based on the presence of arterial transit artifacts (ATA). Selective cerebral angiography will be performed using a biplane digital subtraction angiography system (Artis Zee, Siemens) with a 6F guiding catheter at a frame rate of 7.5 frames per second. The angiographic assessment will evaluate the presence of communicating arteries, the completeness of the Circle of Willis, and the extent of collateral circulation. Hemodynamic compensation will be quantified by analyzing filling times and phase delays across the arterial, parenchymal, and venous phases, expressed in frames. Image analysis will be conducted using Siemens Artis Q angiography software to ensure accurate and reproducible measurements.
Neurological status assessment. The degree of neurological deficit before and after surgery will be evaluated by neurologist using the Baseline neurological examination findings, Modified Rankin Scale (mRS) and National Institutes of Health Stroke Scale (NIHSS) scores). The consequences of prior stroke will also be assessed with the modified Rankin Scale (mRS)15 and the Functional Activities Questionnaire (FAQ)16. Preoperatively and six months after surgery, all patients will be evaluated under a unified diagnostic protocol, with results collected and recorded separately before entering them into a general database with strict personal data encoding.
Cognitive function assessment. Changes in cognitive function before and after surgery and six months postoperatively will be assessed using the neuropsychological tests, measuring both verbal and non-verbal IQ. A standardized battery of neuropsychological tests will be administered by a psychologist to evaluate global cognition, memory, visuospatial skills, and executive function. The Montreal Cognitive Assessment (MoCA) will be used as a screening tool for global cognitive function, assessing domains including attention, executive functions, memory, language, visuospatial skills, abstraction, and orientation17. The Rey Auditory Verbal Learning Test (RAVLT) will be employed to evaluate verbal learning and memory performance, including immediate recall, delayed recall, and recognition memory18. Nonverbal test of Kohs Block Design will be used to assess visuospatial reasoning, problem-solving, and perceptual-motor coordination by requiring participants to reproduce geometric patterns with colored blocks19. The Stroop Test will be applied to measure selective attention, processing speed, and cognitive flexibility by evaluating the ability to inhibit cognitive interference20.
Treatment. All eligible patients with ICA occlusion will undergo standard STA-MCA bypass surgery performed by experienced neurosurgeons. The procedure will be carried out using a standardized microsurgical end-to-side anastomosis technique, which is well established and routinely performed by the participating surgeons21. Intraoperative selection of the donor STA branch and recipient MCA segment will be based on vessel diameter, flow characteristics, and surgical accessibility. Intraoperative bypass patency will be assessed using the "faucet" technique21 in combination with microscopic indocyanine green (ICG) angiography to ensure adequate flow through the anastomosis.
Intraoperative perfusion and blood flow direction assessment Intraoperative perfusion and blood flow direction will be assessed using indocyanine green fluorescent angiography with the Karl Zeiss Pentera 8000 microscope equipped with FLOW 800 technology, which allows real-time visualization of cerebral vessels. All data will be processed and analyzed to create a color map depicting hemodynamic and perfusion delays. This enables comparison of perfusion parameters in the anastomosis region before and after bypass surgery, as well as assessment of blood flow direction and hyperperfusion zones in the brain. The assessment will be performed by neurosurgeons.
Postoperative study procedures.Within 1-3 days after surgery, CTA of the head and neck will be performed to confirm bypass patency, measure the caliber of the donor STA branch, and visualize its course. At 3-5 days postoperatively, ASL-based MR perfusion imaging will be conducted to evaluate cerebral perfusion changes compared with preoperative studies. 3D segmentation and quantitative perfusion mapping will be applied to provide objective assessment of regional perfusion improvements following surgery. Prior to hospital discharge, all patients will undergo a repeat evaluation of neurological status and cognitive function using the same standardized tests as preoperatively.
Follow-up assessment. At six months after surgery, all patients will undergo follow-up assessment including CTA of the head and neck to evaluate bypass patency and measure the caliber of the donor STA branch, MR perfusion imaging with 3D segmentation to assess cerebral perfusion changes, and repeat neurological and neuropsychological evaluations using the same tests administered preoperatively and at discharge (NIHSS, mRS, MoCA, RAVLT, Kohs Block Design, and Stroop tests).
Endpoint evaluation
Primary endpoints (early postoperative assessment):
- Bypass patency assessed by CTA within 1-3 days postoperatively.
- Cerebral perfusion improvement evaluated by ASL MR perfusion imaging 3-5 days postoperatively, including 3D segmentation and quantitative perfusion mapping, as well as assessment for the presence of cerebral hyperperfusion syndrome.
- Surgical safety outcomes, including perioperative stroke, transient ischemic attack (TIA), or other procedure-related complications.
Secondary endpoints (six-month follow-up):
- Clinical outcomes: Occurrence of any stroke events or death.
- Imaging outcomes: CTA of the head and neck to assess long-term bypass patency and measure the caliber of the donor STA branch and MR perfusion imaging wit to evaluate sustained cerebral perfusion changes.
- Functional and cognitive function improvements: Neurological and neuropsychological assessments using the same standardized tests as preoperatively and at discharge.
- MRI perfusions pre and postoperatively after 6 months will be compared in 3 D program models and correlated with neurological and cognitive changes, and additional correlations with donor branch of STA Data processing. All collected data will be meticulously entered into a database, where revascularization progress, the development of collateral circulation, and perfusion changes correlated with neurological and cognitive shifts will be evaluated. All data will undergo statistical processing and analysis to identify patterns and correlations, as well as survival analysis to assess collateral development and psychoneurological dynamics. All participants are expected to complete study visits over the planned 6-months follow-up period.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| patients with chronic occlusive internal carotid artery cerebrovascular disease | Other | Procedure: Revascularization/Conservative management |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Patients with ICA occlusion confirmed by CTA, MRA, and cerebral DSA.
- MRI ASL-confirmed hypoperfusion in the territory of the occluded ICA (decrease of ≥30% compared with the contralateral side)
- Language comprehension is preserved, with mild or no motor aphasia and no significant cognitive impairment.
- Patients aged from 18 to 80 years.
- Modified Rankin Scale (mRS) score 0-2.
Key exclusion criteria (13 listed)
- Patients with large territorial infarction or marked cerebral atrophy on MRI.
- No evidence of regional hypoperfusion on ASL MRI relative to the contralateral hemisphere.
- Patients with a non-functioning STA-MCA bypass
- Patients aged under 18
- Patients with severe somatic conditions or mRS score > 3
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Revascularization/Conservative managementThis study attempts to improve surgical treatment outcomes among people with chronic carotid artery occlusive disease by conducting a comprehensive review of neuroradiological, clinical, and cognitive data. The evaluation involves an extensive angiographic analysis, including pre- and postoperative measurements of superficial temporal artery branch diameters, assessment of the Circle of Willis and collateral pathways, alongside cerebral perfusion metrics, cognitive status, and clinical outcomes. Major focus is directed towards evaluating the degree of intracranial revascularization following to extracranial-intracranial bypass by postoperative angiographic evaluations. | Procedure or surgery | patients with chronic occlusive internal carotid artery cerebrovascular disease |
Primary outcome
STA-MCA bypass patency
Time frame: From enrollment to the further follow-up of 6, 12, and 24 months.
Patency of the extracranial-intracranial bypass will be assessed using CTA of the head and neck and classified as patent or occluded.
Donor superficial temporal artery caliber
Time frame: 6, 12, and 24 months after surgery
Diameter of the donor superficial temporal artery branch at the anastomosis site measured using CTA imaging.
Cerebral perfusion changes
Time frame: 6, 12, and 24 months after surgery
Quantitative cerebral perfusion parameters assessed using MR perfusion imaging with 3D segmentation and compared with preoperative baseline values.
1 secondary outcome
Global cognitive function
Time frame: Preoperatively; at discharge; 6, 12, and 24 months after surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Feb 2026.
- Derived from this study: PubMed 42566397Nurimanov C, Menlibayeva K, Mammadinova I, Turzhanova A, Aidarov S, Batyrkhanov D, Kabykenova A, Makhambetov Y, Kaliyev A. Hemodynamic, neurological, and cognitive outcomes after surgical revascularisation in occlusive cerebrovascular disease: Study protocol for single-arm interventional cohort study. PLoS One. 2026 Aug 7;21(8):e0354103. doi: 10.1371/journal.pone.0354103. eCollection 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Carotid Artery Occlusion
Active, not recruitingObservational study
Symptomatic Carotid Outcomes Registry
Carotid Stenosis, Ischemic Stroke
Not yet recruitingObservational study
PET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With 64Cu-NODAGA-CANF (Multisite)
Carotid Atherosclerosis, Carotid Artery Stenosis Asymptomatic
Recruiting
Isometric Resistance Exercise on Accelerated Atherosclerosis in Hypertension
Atherosclerosis Cardiovascular Disease
Enrolling by invitationEarly Phase 1
Clinical Evaluation of the Safety and Efficacy of "Buyan Huan Wu Tang" Combined With Atorvastatin in the Treatment of Atypical Pneumonia
Moyamoya Disease
Not yet recruitingObservational study
A Prospective, Multicenter, Single Arm Registry of ENROUTE NPS in Conjunction With Carotid WALLSTENT in Chinese Population
Carotid Artery Stenosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Revascularization/Conservative management in people with Carotid Artery Occlusion, run by National Centre for Neurosurgery, Republic of Kazakhstan at 1 site in Kazakhstan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 9 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Kazakhstan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
STA-MCA bypass patency (time frame: From enrollment to the further follow-up of 6, 12, and 24 months.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07396025, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Feb 2026.